Group 1 - The company, Lepu Biopharma-B (02157), has announced a licensing and transfer agreement with Excalipoint for the proprietary T-cell connector TOPAbody platform, involving two preclinical assets [1] - Excalipoint will receive exclusive global rights to develop and commercialize target products, with the company receiving an upfront cash payment of $10 million, equity in Excalipoint, milestone payments up to $847.5 million, and royalties based on sales [2] - The board believes that this licensing deal and Excalipoint's A-round financing will enhance the commercial value of the company's existing product pipeline and technology, supporting its global strategic layout [3] Group 2 - The successful completion of the licensing transaction and A-round financing will allow the company to focus on advancing next-generation ADC drugs and immuno-oncology bispecific/trispecific antibodies, accelerating the commercialization of late-stage products [3]